Gladman D D
Wellesley Hospital, Toronto, Ontario, Canada.
Curr Opin Rheumatol. 1994 Sep;6(5):487-92. doi: 10.1097/00002281-199409000-00006.
In this article, assessment of disease activity in systemic lupus erythematosus (SLE), including available instruments and their use in patients with SLE, is discussed. Several validated measures, including the SLAM (Systemic Lupus Activity Measure), SLEDAI (Systemic Lupus Erythematosus Disease Activity Index), LAI (Lupus Activity Index), ECLAM (European Consensus Lupus Activity Measurement), and that of the BILAG (British Isles Lupus Activity Group) are now available and should be included in studies of new laboratory measures, therapeutic trials, and studies of outcome and prognosis. The prognosis of SLE has improved over the past 4 decades, including 20-year survival rates. With improved survival, other outcome measures such as specific organ function and health status need to be considered. Administration of hydroxychloroquine remains an important part of therapy for SLE. The use of cyclophosphamide should be reserved for severe manifestations of the disease. Newer forms of therapy, particularly immunotherapy, have been tested in animal models.
本文讨论了系统性红斑狼疮（SLE）疾病活动度的评估，包括可用的评估工具及其在SLE患者中的应用。目前已有几种经过验证的评估方法，包括SLAM（系统性狼疮活动度测量）、SLEDAI（系统性红斑狼疮疾病活动指数）、LAI（狼疮活动指数）、ECLAM（欧洲狼疮活动度共识测量）以及BILAG（英伦三岛狼疮活动组）的评估方法，这些方法应纳入新实验室检测、治疗试验以及结局和预后研究中。在过去40年里，SLE的预后有所改善，包括20年生存率。随着生存率的提高，需要考虑其他结局指标，如特定器官功能和健康状况。羟氯喹的应用仍然是SLE治疗的重要组成部分。环磷酰胺的使用应仅限于该疾病的严重表现。新型治疗方法，特别是免疫疗法，已在动物模型中进行了测试。
